Pfizer To Pay $2.3B In Bextra Off-Label Marketing Suit
The settlement, which still needs court approval, was reached with the office of U.S. Attorney Michael Sullivan of the District of Massachusetts.
According to a statement put out by Pfizer, the deal will resolve “previously disclosed investigations regarding allegations of past off-label promotional practices concerning Bextra, as well as other open investigations.”
The company added that its net income for the...
To view the full article, register now.